Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

01-09-2009 | Uitgave 7/2009 Open Access

Quality of Life Research 7/2009

Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial

Tijdschrift:
Quality of Life Research > Uitgave 7/2009
Auteurs:
Desmond Curran, Carmelo Pozzo, Jerzy Zaluski, Magdalena Dank, Carlo Barone, Vahur Valvere, Suayib Yalcin, Christian Peschel, Miklós Wenczl, Erdem Goker, Roland Bugat
Belangrijke opmerkingen
This study was sponsored by Pfizer, Inc. The phase III part of this study has been presented at the Annual Conference of the American Society of Clinical Oncology, Orlando (ASCO), FL, 2005 and the ASCO Gastrointestinal Cancers Symposium, Hollywood, FL, 2005.

Abstract

Purpose

The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented.

Methods

Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling.

Results

A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm.

Conclusion

There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.

Onze productaanbevelingen

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Literatuur
Over dit artikel

Andere artikelen Uitgave 7/2009

Quality of Life Research 7/2009 Naar de uitgave